, April 6, 2011
/PRNewswire/ -- Sagent Pharmaceuticals (the "Company"), announced that it has commenced an initial public offering of 5,000,000 shares of common stock.
The estimated range for the initial public offering price is $14.00 to $16.00 per share. The Company has applied to list its common stock on The NASDAQ Global Market under the proposed symbol "SGNT." The Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock on the same terms and conditions. The Company intends to use substantially all of the net proceeds from this offering for general corporate purposes.
Morgan Stanley & Co. Incorporated, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and Jefferies & Company, Inc. will act as the joint bookrunners for the offering. Needham & Company, LLC and RBC Capital Markets, LLC will act as the co-managers for the offering. The offering will be made only by means of a prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, NY 10013, by telephone at (917) 606-8474, or by e-mail at firstname.lastname@example.org; from Merrill Lynch, Pierce, Fenner & Smith Incorporated, 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department, or by e-mail at email@example.com; or from Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
SOURCE Sagent Pharmaceuticals